The startup develops diagnostic tool kits that utilize rapid molecular genetic testing to enable early detection of viral diseases, including COVID-19. By providing accurate identification of clinical biomarkers, the kits facilitate timely contact tracing and enhance point-of-care testing with cost-effective solutions.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The timely and accurate detection of viral diseases, including COVID-19, is crucial for effective contact tracing and point-of-care testing. Traditional methods can be slow or lack the sensitivity needed for early diagnosis. This can lead to delays in treatment and increased spread of infectious diseases.
Solution
GeneMe develops qPCR-based diagnostic kits designed for rapid molecular genetic testing of infectious diseases. Their patented technology allows for the development of new genetic tests within a short timeframe. The kits facilitate the identification of clinical biomarkers, enabling faster and more accurate diagnoses. This supports timely contact tracing and enhances point-of-care testing capabilities for healthcare professionals.
Target Audience
The primary customers are professionals in genetic laboratory diagnostics, including research institutions, hospitals, and diagnostic centers.
Features
- qPCR diagnostic kits for SNPs, STIs, and IDs
- Patented technology that enables rapid development of new genetic tests
- Focus on increasing accuracy and reducing the time of genetic analysis
- Streamlined workflow for easy integration into existing laboratory settings